ENTX vs. BBOT
ENTX (Entera Bio Ltd) and BBOT (BridgeBio Oncology Therapeutics, Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. At a 0.24 correlation, their price movements are largely independent.
Performance
ENTX vs. BBOT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ENTX achieves a -20.10% return, which is significantly higher than BBOT's -40.10% return.
ENTX
- 1D
- 4.73%
- 1M
- 25.00%
- YTD
- -20.10%
- 6M
- -11.93%
- 1Y
- -20.92%
- 3Y*
- 23.26%
- 5Y*
- -23.99%
- 10Y*
- —
BBOT
- 1D
- -4.70%
- 1M
- -12.28%
- YTD
- -40.10%
- 6M
- -37.13%
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
ENTX vs. BBOT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | |
|---|---|---|
ENTX Entera Bio Ltd | -20.10% | 3.19% |
BBOT BridgeBio Oncology Therapeutics, Inc | -40.10% | 22.75% |
Correlation
The correlation between ENTX and BBOT is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (All Time) Calculated using the full available price history since Aug 12, 2025 | 0.24 |
Fundamentals
ENTX:
$74.02M
BBOT:
$600.24M
ENTX:
-$0.11
BBOT:
-$3.90
ENTX:
$0.00
BBOT:
$0.00
ENTX:
-$15.00K
BBOT:
-$194.00K
ENTX:
-$12.42M
BBOT:
-$168.31M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ENTX vs. BBOT — Risk / Return Rank
ENTX
BBOT
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
ENTX vs. BBOT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Entera Bio Ltd (ENTX) and BridgeBio Oncology Therapeutics, Inc (BBOT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ENTX | BBOT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | 1.03 | — | — |
| Calmar ratioReturn relative to maximum drawdown | -0.31 | — | — |
| Martin ratioReturn relative to average drawdown | -0.50 | — | — |
Loading charts...
Drawdowns
ENTX vs. BBOT - Drawdown Comparison
The maximum ENTX drawdown since its inception was -93.15%, which is greater than BBOT's maximum drawdown of -48.14%. Use the drawdown chart below to compare losses from any high point for ENTX and BBOT.
Loading charts...
Drawdown Indicators
| ENTX | BBOT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.15% | -48.14% | -45.01% |
Max Drawdown (1Y)Largest decline over 1 year | -68.15% | — | — |
Max Drawdown (3Y)Largest decline over 3 years | -68.15% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -92.05% | — | — |
Current DrawdownCurrent decline from peak | -78.77% | -45.38% | -33.39% |
Average DrawdownAverage peak-to-trough decline | -68.15% | -20.56% | -47.59% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 42.00% | — | — |
Volatility
ENTX vs. BBOT - Volatility Comparison
Loading charts...
Volatility by Period
| ENTX | BBOT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 26.30% | — | — |
Volatility (6M)Calculated over the trailing 6-month period | 72.34% | — | — |
Volatility (1Y)Calculated over the trailing 1-year period | 87.26% | 70.40% | +16.86% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 87.15% | 70.40% | +16.75% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 110.26% | 70.40% | +39.86% |
Dividends
ENTX vs. BBOT - Dividend Comparison
Neither ENTX nor BBOT has paid dividends to shareholders.
Financials
ENTX vs. BBOT - Financials Comparison
This section allows you to compare key financial metrics between Entera Bio Ltd and BridgeBio Oncology Therapeutics, Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ENTX and BBOT have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for ENTX and BBOT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer